ERA - Leading European Nephrology

My ERA ERA'ya Katıl

Home | Video pages | Webcast | SGLT2 inhibitors and haemoglobin increase: a possible explanation of the cardiovascular benefits?

SGLT2 inhibitors and haemoglobin increase: a possible explanation of the cardiovascular benefits?

Paylaş

https://www.youtube.com/watch?v=RyTt7lNI3Xc kopyala

Other e-seminars from EuReCa-M

Thyroid Hormone in CKD patients with diabetes: what is known, what is new

Long-term cardiovascular complications following AKI

What does the Cardiovascular-Kidney-Metabolic (CKM) Syndrome mean for nephrologists?

The impact of novel anticancer therapies on blood pressure and kidney function in patients with CKD

Heart failure in patients with CKD: diagnosis and therapeutic approaches

Calcification propensity: from biomarker to treatment target?

Assessment and management of hypertension in dialysis patients

GLP-1 receptor agonists in patients with CKD not on dialysis; beyond cardiorenal protection

Echocardiography or Cardiac Magnetic resonance Imaging (or both) for cardiac assessment in CKD patients?

Physical Activity in CKD patients: time to overcome nephrologist’s inertia

Let´s talk about sex: disparities in the outcomes and quality of care of men and women with kidney disease